Physician profile
Michael Prostko
NPI 1114955945
$282.92
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $54.70 · 2021: $19.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $115.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.27 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $24.43 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.73 | 2019 | |
| Pfizer INC. | $22.19 | 2019 | |
| Abbott Laboratories | $19.90 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.92 | 2019 | |
| Irhythm Technologies, INC. | $16.54 | 2019 | |
| Merck Sharp & Dohme LLC | $13.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Prostko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.